The scientists say when activated, one protein, called the short form, stops glioblastoma cells from replicating their DNA, and the other, called the long form, prevents cell division if the DNA has already been replicated, explains Rebecca Riggins, PhD, assistant professor of oncology at Georgetown Lombardi. The study was posted online Dec. …
The new molecules — synthetic antibody mimics (SyAMs) — attach themselves simultaneously to disease cells and disease-fighting cells. The result is a highly targeted immune response, similar to the action of natural human antibodies. “Unlike antibodies, however, our molecules are synthetic organic compounds that are approximately one-twentieth the size of antibodies,” said David A…
MPM is a fatal cancer associated with asbestos exposure that develops on the outer linings of the lungs. The 3-year survival rate is only 8% and most MPM patients are diagnosed with late stage disease with limited therapeutic options…
Previous studies traced reactions such as pain, itching and rashes at the injection sites of many drugs to part of the immune system known as mast cells. When specialized receptors on the outside of mast cells detect warning signals known as antibodies, they spring into action, releasing histamine and other substances that spark inflammation and draw other immune cells into the area. Those antibodies are produced by other immune cells in response to bacteria, viruses or other perceived threats…
Causes of death vary widely by country, but, at the global level, drug use disorders and chronic kidney disease account for some of the largest percent increases in premature deaths since 1990. Death rates from some cancers, including pancreatic cancer and kidney cancer, also increased. …
A gene normally involved in the regulation of embryonic development can trigger the transition of cells into more mobile types that can spread without regard for the normal biological controls that restrict metastasis, the new study shows. Analysis of downstream signaling pathways of this gene, called SNAIL, could be used to identify potential targets for scientists who are looking for ways to block or slow metastasis. “This gene relates directly to the mechanism that metastatic cancer cells use to move from one location to another,” said Michelle Dawson, an assistant professor in the School of Chemical and Biomolecular Engineering at the Georgia Institute of Technology…
Studies linking migraine to breast cancer have reported inconsistent results. …
The scientists say when activated, one protein, called the short form, stops glioblastoma cells from replicating their DNA, and the other, called the long form, prevents cell division if the DNA has already been replicated, explains Rebecca Riggins, PhD, assistant professor of oncology at Georgetown Lombardi. The study was posted online Dec…
An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in progression-free survival (PFS0 for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment letrozole and palbociclib, compared to letrozole alone. …
An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in progression-free survival (PFS0 for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment letrozole and palbociclib, compared to letrozole alone. “We’re essentially putting the brakes on cell proliferation and causing these tumor cells to stop growing,” said Dr. Richard Finn, associate professor of medicine at UCLA and lead author of the study…